Understanding how blocking CRAF can shrink KRAS-driven lung cancer
Mechanistic Determination of KRAS Lung Cancer Regression upon CRAF Suppression
['FUNDING_CAREER'] · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · NIH-11056723
This study is looking at how blocking a protein called CRAF can help shrink non-small cell lung cancer, and it aims to find out how this works and how the tumor's surroundings might change when CRAF is reduced, which could lead to better treatments for people with this type of lung cancer.
Quick facts
| Phase | ['FUNDING_CAREER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO (nih funded) |
| Locations | 1 site (SAN FRANCISCO, UNITED STATES) |
| Trial ID | NIH-11056723 on ClinicalTrials.gov |
What this research studies
This research investigates the mechanisms behind the regression of non-small cell lung cancer (NSCLC) when the CRAF protein is suppressed. By using a specially designed human lung cancer cell line, the study aims to identify the specific parts of CRAF that contribute to tumor growth and the biological pathways involved in this process. The researchers will also explore how changes in the tumor environment affect cancer progression when CRAF is knocked down. This work could lead to new treatment strategies for patients with KRAS-driven lung cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with non-small cell lung cancer that has mutations in the KRAS gene.
Not a fit: Patients with lung cancer that does not involve KRAS mutations or those with other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide new therapeutic options for patients with KRAS-driven lung cancer, potentially improving survival rates.
How similar studies have performed: Previous research has shown promise in targeting KRAS-related pathways, but this specific approach focusing on CRAF suppression is relatively novel.
Where this research is happening
SAN FRANCISCO, UNITED STATES
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO — SAN FRANCISCO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WANG, VICTORIA — UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- Study coordinator: WANG, VICTORIA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.